Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma

被引：18

作者：

Zhang, Jing ^{[1
,2
]}

Lu, Xueying ^{[1
,2
,4
]}

Li, Jianyong ^{[1
,2
,3
]}

Miao, Yi ^{[1
,2
,3
]}

机构：

[1] Nanjing Med Univ, Jiangsu Prov Hosp, Dept Hematol, Affiliated Hosp 1, Nanjing, Peoples R China

[2] Nanjing Med Univ, Key Lab Hematol, Nanjing, Peoples R China

[3] Pukou CLL Ctr, Nanjing, Peoples R China

[4] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, Suzhou, Peoples R China

来源：

BIOMARKER RESEARCH | 2022年 / 10卷 / 01期

关键词：

BTK inhibitors; BCL2; inhibitors; Chronic lymphocytic leukemia; Mantle cell lymphoma; ATRIAL-FIBRILLATION; TREATMENT-NAIVE; IBRUTINIB; VENETOCLAX; OBINUTUZUMAB; RISK; PROLIFERATION; ACALABRUTINIB; CHLORAMBUCIL; COMBINATION;

D O I：

10.1186/s40364-022-00357-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in multiple clinical trials. The second-generation BTK inhibitors, including acalabrutinib and zanubrutinib, also show remarkable efficacies. However, using BTK inhibitors as monotherapies requires continuous treatment. Resistance to BTK inhibitors and severe side effects unavoidably occur during BTK inhibitor monotherapy, frequently resulting in treatment failure. The addition of the BCL2 inhibitor venetoclax to BTK inhibitor may improve the therapeutic effects and result in deeper responses, providing a potential fixed-duration treatment, especially for patients with CLL. In this review, by focusing on CLL and MCL, we discussed the rationale for the combinational use and summarized the current data on the combinations of BTK inhibitors and venetoclax in patients with CLL and MCL.

引用

页数：11

共 71 条

[1]

Allan JN., 2021, EHA LIB, V324555, pS147

[2] Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials [J].

Brown, Jennifer R. ;

Moslehi, Javid ;

O'Brien, Susan ;

Ghia, Paolo ;

Hillmen, Peter ;

Cymbalista, Florence ;

Shanafelt, Tait D. ;

Fraser, Graeme ;

Rule, Simon ;

Kipps, Thomas J. ;

Coutre, Steven ;

Dilhuydy, Marie-Sarah ;

Cramer, Paula ;

Tedeschi, Alessandra ;

Jaeger, Ulrich ;

Dreyling, Martin ;

Byrd, John C. ;

Howes, Angela ;

Todd, Michael ;

Vermeulen, Jessica ;

James, Danelle F. ;

Clow, Fong ;

Styles, Lori ;

Valentino, Rudy ;

Wildgust, Mark ;

Mahler, Michelle ;

Burger, Jan A. .

HAEMATOLOGICA, 2017, 102 (10) :1796-1805

[3] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[4] Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study [J].

Burger, Jan A. ;

Barr, Paul M. ;

Robak, Tadeusz ;

Owen, Carolyn ;

Ghia, Paolo ;

Tedeschi, Alessandra ;

Bairey, Osnat ;

Hillmen, Peter ;

Coutre, Steven E. ;

Devereux, Stephen ;

Grosicki, Sebastian ;

McCarthy, Helen ;

Simpson, David ;

Offner, Fritz ;

Moreno, Carol ;

Dai, Sandra ;

Lal, Indu ;

Dean, James P. ;

Kipps, Thomas J. .

LEUKEMIA, 2020, 34 (03) :787-798

[5] Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia [J].

Burger, Jan A. ;

Sivina, Mariela ;

Jain, Nitin ;

Kim, Ekaterina ;

Kadia, Tapan ;

Estrov, Zeev ;

Nogueras-Gonzalez, Graciela M. ;

Huang, Xuelin ;

Jorgensen, Jeffrey ;

Li, Jianling ;

Cheng, Mei ;

Clow, Fong ;

Ohanian, Maro ;

Andreeff, Michael ;

Mathew, Thomas ;

Thompson, Philip ;

Kantarjian, Hagop ;

O'Brien, Susan ;

Wierda, William G. ;

Ferrajoli, Alessandra ;

Keating, Michael J. .

BLOOD, 2019, 133 (10) :1011-1019

[6] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[7] Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia [J].

Cervantes-Gomez, Fabiola ;

Lamothe, Betty ;

Woyach, Jennifer A. ;

Wierda, William G. ;

Keating, Michael J. ;

Balakrishnan, Kumudha ;

Gandhi, Varsha .

CLINICAL CANCER RESEARCH, 2015, 21 (16) :3705-3715

[8] BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia [J].

Chen, S-S ;

Chang, B. Y. ;

Chang, S. ;

Tong, T. ;

Ham, S. ;

Sherry, B. ;

Burger, J. A. ;

Rai, K. R. ;

Chiorazzi, N. .

LEUKEMIA, 2016, 30 (04) :833-843

[9] Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL) [J].

Davids, Matthew S. ;

Lampson, Benjamin L. ;

Tyekucheva, Svitlana ;

Crombie, Jennifer L. ;

Ng, Samuel ;

Kim, Austin I. ;

Weinstock, Matthew ;

Lowney, Jessica ;

Pazienza, Samantha ;

Montegaard, Josie ;

Patterson, Victoria ;

Jacobson, Caron A. ;

LaCasce, Ann S. ;

Armand, Philippe ;

Arnason, Jon E. ;

Fisher, David C. ;

Brown, Jennifer R. .

BLOOD, 2020, 136

[10] Targeting BCL-2 in B-cell lymphomas [J].

Davids, Matthew S. .

BLOOD, 2017, 130 (09) :1081-1088

← 1 2 3 4 5 6 7 8 →